Immuneering Corporation Class A Common Stock (IMRX) Stock Price

IMRXStock

$3.59−35.20%52W

Market Cap$232.26M

P/E—

PEG Ratio—

Div yield—

Beta0.35

IMRX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-43.55%

Price vs S&P 500 (4W)-17.82%

VGM Score35.75

Book Value / Share (Quarterly)$2.95

P/TBV (Annual)1.95x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.88

Price vs S&P 500 (YTD)-57.37%

Gross Margin (TTM)28.00%

Net Profit Margin (TTM)-9610.00%

EPS (TTM)$-1.03

10-Day Avg Trading Volume0.85M

EPS Excl Extra (TTM)$-1.03

EPS (Annual)$-2.03

ROI (Annual)-147.39%

Gross Margin (Annual)50.00%

Cash / Share (Quarterly)$2.32

ROA (Last FY)-115.72%

EBITD / Share (TTM)$-1.08

ROE (5Y Avg)-64.35%

Operating Margin (TTM)-9778.00%

Cash Flow / Share (Annual)$-1.77

P/B Ratio1.22x

P/B Ratio (Quarterly)1.69x

Net Income / Employee (Annual)$-1,150,900

EV / Revenue (TTM)381.88x

Net Interest Coverage (TTM)-25.59x

ROA (TTM)-25.74%

EPS Incl Extra (Annual)$-2.03

Current Ratio (Annual)17.50x

Quick Ratio (Quarterly)18.47x

3-Month Avg Trading Volume0.91M

52-Week Price Return-35.20%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.94

P/S Ratio (Annual)725.82x

Asset Turnover (Annual)0.00x

52-Week High$8.48

EPS Excl Extra (Annual)$-2.03

CapEx CAGR (5Y)23.25%

26-Week Price Return-33.64%

Quick Ratio (Annual)17.16x

13-Week Price Return-22.63%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)19.47x

Enterprise Value$190.94M

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-15784.38%

Cash / Share (Annual)$1.16

3-Month Return Std Dev51.94%

Net Income / Employee (TTM)$-1,080,700

ROE (Last FY)-147.39%

EPS Basic Excl Extra (Annual)$-2.03

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.03

Receivables Turnover (Annual)3.20x

ROI (TTM)-27.15%

P/S Ratio (TTM)464.53x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.32

Price vs S&P 500 (52W)-50.73%

Year-to-Date Return-45.44%

5-Day Price Return-6.99%

EPS Normalized (Annual)$-2.03

ROA (5Y Avg)-54.72%

Net Profit Margin (Annual)-15784.38%

Month-to-Date Return-12.33%

Cash Flow / Share (TTM)$-1.85

EBITD / Share (Annual)$-2.12

Operating Margin (Annual)-16168.75%

ROI (5Y Avg)-64.35%

EPS Basic Excl Extra (TTM)$-1.03

P/TBV (Quarterly)1.70x

P/B Ratio (Annual)1.94x

Pretax Margin (TTM)-9672.00%

Book Value / Share (Annual)$1.33

Price vs S&P 500 (13W)-25.31%

Beta0.35x

Revenue / Share (TTM)$0.00

ROE (TTM)-27.15%

52-Week Low$3.38

vGradeD

mGradeC

vgmGradeD

IMRX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.27	-$0.27	-0.53%(-$0.00)
Q1 2026	May 15, 2026	-$0.25	-$0.21	+16.67%(+$0.04)
Q4 2025	Mar 6, 2026	-$0.31	-$0.18	+42.25%(+$0.13)
Q3 2025	Nov 12, 2025	-$0.39	-$0.38	+2.15%(+$0.01)
Q2 2025	Aug 13, 2025	-$0.40	-$0.40	-0.50%(-$0.00)

IMRX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.25

4.23

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
IMRXImmuneering Corporation Class A Common Stock	D	—	C	464.5x	—	28.0%	—	$3.59
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Immuneering Corporation Class A Common Stock

Immuneering is a biopharmaceutical company developing oncology and neurology treatments using its proprietary Disease Cancelling Technology platform, which leverages computational biology and translational bioinformatics. The company generates revenue from both internal drug discovery programs and by licensing its computational capabilities to other pharmaceutical and biotechnology companies.